![Robert J. de Vaere](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert J. de Vaere
Direttore Finanziario/CFO presso VisioMedtrics, Inc.
Profilo
Robert J.
de Vaere is currently the Chief Financial Officer & Director at VisioMedtrics, Inc. Prior to his current position, he held various roles including Director-Finance & Business Management at Kaiser Electro-Optics, Inc. from 1993 to 1996, Chief Financial Officer & VP-Administration at iVOW, Inc. from 1996 to 2000, Chief Financial Officer & Vice President at Epimmune, Inc. from 2000 to 2005, Chief Financial Officer, Secretary & Executive VP at Horizon Therapeutics Plc from 2008 to 2014, Chief Financial Officer at Nexa Orthopedics, Inc. in 2006, Chief Financial Officer & VP-Administration at IDM Pharma, Inc. in 2005, Chief Financial Officer & Senior VP-Administration at IDM Pharma, Inc. from 2007 to 2009, Chief Financial Officer & Executive Vice President at Horizon Therapeutics, Inc. from 2008 to 2010, Controller at Kaiser Rollmet from 1991 to 1993, Chief Financial Officer, Secretary & Executive VP at Horizon Pharma, Inc. from 2010 to 2014, and Chief Financial Officer & Executive Vice President at Horizon Therapeutics USA, Inc. from 2008 to 2014.
He obtained his undergraduate degree from the University of California, Los Angeles in 1980.
Posizioni attive di Robert J. de Vaere
Società | Posizione | Inizio |
---|---|---|
VisioMedtrics, Inc. | Direttore Finanziario/CFO | 06/08/2010 |
Precedenti posizioni note di Robert J. de Vaere
Società | Posizione | Fine |
---|---|---|
Horizon Pharma, Inc.
![]() Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Direttore Finanziario/CFO | 30/09/2014 |
Horizon Therapeutics USA, Inc.
![]() Horizon Therapeutics USA, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL. | Direttore Finanziario/CFO | 30/09/2014 |
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Direttore Finanziario/CFO | 30/09/2014 |
Horizon Therapeutics, Inc.
![]() Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Direttore Finanziario/CFO | 05/04/2010 |
IDM Pharma, Inc.
![]() IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Direttore Finanziario/CFO | 01/06/2009 |
Formazione di Robert J. de Vaere
University of California, Los Angeles | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 11 |
---|---|
Nexa Orthopedics, Inc.
![]() Nexa Orthopedics, Inc. Medical SpecialtiesHealth Technology Nexa Orthopedics, Inc. manufactures and markets devices for orthopedic and podiatric surgeons. It offers a line of implants, devices, and biologic products for surgeons. The company was founded in 2004 and is headquartered in San Diego, CA | Health Technology |
Epimmune, Inc. | Health Technology |
Kaiser Electro-Optics, Inc. | |
Kaiser Rollmet | |
Horizon Therapeutics, Inc.
![]() Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | Health Technology |
Horizon Therapeutics USA, Inc.
![]() Horizon Therapeutics USA, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL. | Health Technology |
VisioMedtrics, Inc. | |
IDM Pharma, Inc.
![]() IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | Health Technology |
Horizon Pharma, Inc.
![]() Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | Health Technology |
iVOW, Inc.
![]() iVOW, Inc. Medical/Nursing ServicesHealth Services iVOW Inc, formerly Vista Medical Technologies, Inc. (VMTI) is a disease state management company focused on the treatment of morbid obesity. The company operates two business units: Obesity Surgical and Medical Management Services and Visualization Technology. The Obesity Surgical and Medical Management Services business, operated by the Company's wholly owned subsidiary, VOW Solutions, Inc., provides services to physicians and hospitals involved in the surgical treatment of morbid obesity. Its services include management of the Company's original product offering, the Laparoscopic Bariatric Surgery Preceptorship, an introduction to starting a minimally invasive gastric bypass surgical program. In addition, the business offers consulting and program management services, which enable the efficient operation of obesity surgery programs. | Health Services |
Horizon Therapeutics Plc
![]() Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Borsa valori
- Insiders
- Robert J. de Vaere